Skip to main content
logo
Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India flag India · Delayed Price · Currency is INR
1,198.00
+21.25 (1.81%)
At close: Oct 1, 2026

Symbiotec Pharmalab Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
8,8418,6917,5167,1625,6656,818
Revenue Growth
23.44%15.65%4.93%26.43%-16.91%-
Gross Profit
5,4165,2484,3243,7592,5883,296
Operating Income
1,6311,8711,6111,339441.961,072
Net Income
940.21,099967.841,002234.86775.27
Earnings Per Share
14.9819.0017.3618.004.3014.18
EPS Growth
-16.73%9.45%-3.54%319.01%-69.71%-

Revenue by Geography
Chart
Fiscal YearFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '25 Mar '24 Mar '23 Mar '22
India
2,8653,3682,8672,6723,216
Europe
2,5302,2712,124--
United States
1,140302.02642.6--
Rest of World
2,1571,5751,528--
Total
8,6917,5167,1625,6656,818

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
101.25101.25264.6975.6354.2495.41
Total Debt
3,9103,9105,4442,5062,200657.87
Net Cash (Debt)
-3,809-3,809-5,180-2,430-2,145-562.46
Net Cash Growth
------
Net Cash Per Share
-60.71-65.86-92.89-43.66-39.23-10.29

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-1,746472.561,875692.38177.11
Capital Expenditures
--2,257-3,081-2,098-2,244-723.5
Free Cash Flow
--511.26-2,609-222.69-1,552-546.39
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
61.26%60.39%57.54%52.49%45.68%48.34%
Operating Margin
18.44%21.53%21.43%18.69%7.80%15.72%
Pretax Margin
14.26%17.65%19.56%18.29%6.75%15.50%
Profit Margin
10.63%12.64%12.88%13.99%4.15%11.37%
FCF Margin
--5.88%-34.71%-3.11%-27.39%-8.01%